Compare Regeneron Pharmaceuticals Inc (REGN) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while First Trust Cloud Computing ETF trades at $133.07. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while First Trust Cloud Computing ETF pays none, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | SKYY | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $155.17 |
52-Week Low | $545.46 | $104.16 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SKYY trades at $136.02, down 0.06% on the day, with a bullish technical signal driven by moving averages. The ETF offers diversified exposure to the cloud computing sector, though key valuation and profitability metrics are not disclosed in the provided data. Recent news highlights ongoing investor interest in technology ETFs and the growth potential of AI-driven cloud platforms.
The outlook for SKYY is supported by strong inflows into technology ETFs and enterprise AI spending, but risks include sector volatility and competitive pressures. Analyst coverage remains positive on cloud computing's long-term growth, though specific price targets and institutional holdings data are needed for a fuller assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
